Clinical Trials Logo

Coronary Stenosis clinical trials

View clinical trials related to Coronary Stenosis.

Filter by:

NCT ID: NCT03632785 Enrolling by invitation - Clinical trials for Cardiovascular Risk Factor

Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography

Start date: March 27, 2017
Phase:
Study type: Observational

Approximately 50% of coronary events occur in previously asymptomatic patients. Thus, the early detection of the individuals at higher risk became an important research target within the current cardiology. The various clinical scores used present a predictive accuracy for ischemic events, evaluated by the ROC curve, which ranges from 0.73 to 0, 79. Therefore, the introduction of new non-invasive techniques for the detection of atherosclerosis aims to allow a more adequate classification of risk. The development of radiological techniques, fundamentally coronary angiotomography of multiple detectors (CAMD) and electron beam computed tomography-EBCT‖, demonstrated that the degree of coronary calcification correlates with endothelial lesion and individual prognosis in the long term. Notably, the calcium score has a weak correlation with the severity of coronary stenosis per se, possibly due to variations in arterial remodeling due to coronary calcification. On the other hand, the CAMD allows the detection of a small magnitude atheromatous disease, not diagnosed clinically, nor by tests provoking ischemia, or even by coronary catheterization. The clinical relevance of the small magnitude atheromatous disease diagnosed by the ACMD and its correlation with plaque vulnerability markers, mainly platelet aggregation, vascular reactivity, and inflammation are still not well determined. This is a case and control study and we will enrolled 90 patients with low and medium risk of cardiovascular event whose cases should present discrete plaques in the CAMD e controls should present none plaque in coronary stenosis

NCT ID: NCT03606330 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Systemic, Pancoronary and Local Coronary Vulnerability

VIP
Start date: August 1, 2018
Phase:
Study type: Observational

• The aim of the VIP study is to investigate the impact of vulnerability markers (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and vulnerability mapping for pancoronary vulnerability, and imaging-based plaque features for systemic vulnerability) on the rate of major adverse cardiovascular events caused by progression of the non-culprit lesion in patients with acute ST or non-ST segment elevation myocardial infarction who undergo revascularization of the culprit lesion during the acute event. Furthermore, the study will evaluate the rate of progression of non-culprit lesions towards a higher degree of vulnerability, based on coronary computed tomography angiographic assessment at 1 year after enrollment.

NCT ID: NCT03588481 Not yet recruiting - Coronary Disease Clinical Trials

IRIS- DESyne X2 in the IRIS-DES Registry

IRIS DESyne X2
Start date: August 30, 2018
Phase:
Study type: Observational

This study evaluates effectiveness and safety of DESyne X2 in Routine Clinical Practice.

NCT ID: NCT03588455 Completed - Coronary Stenosis Clinical Trials

Pronostic Impact of Flow Fraction Reserve on Intermediate Stenoses

Start date: January 1, 2018
Phase:
Study type: Observational

The intermediate coronary stenoses defined by a degree of stenosis from 40 to 70 % are frequent. The Flow Fraction Reserve (FFR), realized during coronarography, is an hemodynamic evaluation by the functional impact measuring the loss of load in upstream / approval of the stenosis inthe basal state and in situation of hyperemia led by adenosine. Further to the study FAME, the threshold of definition of the significant character of one Stenosis was fixed for a value of FFR = 0,80. However, the impact forecasts intermediate values badly known rest. We hypothetized that coronary stenosis associated with borderline values of FFR 0.81-0.85 were associated with a higher rate of clinical events than those with a FFR >0.85

NCT ID: NCT03508219 Not yet recruiting - Coronary Stenosis Clinical Trials

POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)

POLBOS LM
Start date: April 2018
Phase: N/A
Study type: Interventional

The primary objective of this study is to study the safety and efficacy of the BiOSS LIM C with respect to Patient oriented Composite Endpoint (PoCE) at 12 months in a "real world" left-main bifurcation population and as compared with a prespecified performance goal.

NCT ID: NCT03507777 Recruiting - Clinical trials for Coronary Artery Disease

ILUMIEN IV: OPTIMAL PCI

Start date: March 26, 2018
Phase: N/A
Study type: Interventional

The objective of this clinical investigation is to demonstrate the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy as compared to an angiography-guided stent implantation strategy in achieving larger post-PCI lumen dimensions and improving clinical cardiovascular outcomes in patients with high-risk clinical characteristics and/or with high-risk angiographic lesions.

NCT ID: NCT03502083 Completed - Type2 Diabetes Clinical Trials

Human Vasodilatory Effect of GLP-1

Start date: December 1, 2015
Phase: N/A
Study type: Interventional

Comprehensive assessment of human vasodilatory effect of GLP-1 in forearm and coronary arteries

NCT ID: NCT03497637 Not yet recruiting - Clinical trials for Coronary Artery Disease

Comparison of Pd/Pa Versus FFR in Intermediate Coronary Stenoses

LIPSIASTRATEGY
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

This is a prospective, randomized, controlled, multicenter, open-label study designed to assess whether Pd/Pa is non-inferior to FFR when used to guide treatment of intermediate coronary artery stenosis

NCT ID: NCT03484234 Not yet recruiting - Clinical trials for Coronary Artery Disease

Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)

LONG-DES VII
Start date: August 30, 2018
Phase: N/A
Study type: Interventional

This study compares angiographic and clinical outcomes in patients with long coronary lesions treated with sirolimus-eluting stent (Ultimaster stent) or everolimus-eluting stent (Xience Alpine stent). The study uses a randomized, multicenter, controlled design approach.

NCT ID: NCT03465644 Not yet recruiting - Coronary Stenoses Clinical Trials

TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI

TAILORED-CHIP
Start date: October 15, 2018
Phase: Phase 4
Study type: Interventional

This study evaluates the efficacy and safety of tailored antithrombotic therapy with early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month post-PCI) deescalated (clopidogrel alone) strategy in patients undergoing high-risk complex PCI as compared with standard Dual Antiplatelet Therapy(aspirin and clopidogrel for 12 months).